Table 2.

Lifetime healthcare costs, QALYs, and incremental cost-effectiveness ratio (cost (€) per QALY gained) of GR risedronate compared with generic risedronate, alendronate, and no treatment at the age of 70 years

	GR risedronate	Generic risedronate	Alendronate	No treatment	Incremental
					Vs generic risedronate	Vs alendronate	Vs no treatment
BMD T-score ≤ − 2.5 and prevalent vertebral fractures
Treatment cost	343	191	298	0	153	45	343
Fractures-related cost	27,051	27,182	27,091	27,418	− 132	− 40	− 367
Total healthcare cost	27,394	27,373	27,390	27,418	21	5	− 24
QALY	9.4902	9.4812	9.4881	9.4664	0.0090	0.0021	0.0238
ICER (€ per QALY gained)					2341	2037	Cost-saving*
BMD T-score ≤ − 2.5
Treatment cost	343	191	298	0	152	45	343
Fractures-related cost	16,706	16,743	16,728	16,898	− 37	− 22	− 192
Total healthcare cost	17,050	16,933	17,026	16,898	117	24	152
QALY	10.0674	10.0621	10.0655	10.0564	0.0053	0.0019	0.011
ICER (€ per QALY gained)					21,875	12,548	13,707
Prevalent vertebral fractures
Treatment cost	343	191	298	0	152	45	343
Fractures-related cost	15,878	15,929	15,899	16,029	− 51	− 21	− 151
Total healthcare cost	16,221	16,119	16,198	16,029	102	23	192
QALY	9.8881	9.8830	9.8868	9.8736	0.0051	0.0013	0.0145
ICER (€ per QALY gained)					19,922	18,259	13,311

GR, gastro-resistant; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year

*Additional treatment costs lower than fractures-related cost saved with more prevented fractures